Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 ... Novo Nordisk's once-daily injectable weight loss therapy Saxenda (liraglutide) has been a slow ...

U.S. equities were mostly edging higher at midday with the market watching for developments in U.S.-China trade negotiations.

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...